| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
When applied to human non-small cell lung cancer (NSCLC) tumor cell lines (H460 and A549) that have wild-type p53, fenbendazole (1 uM; 24 hours) dramatically slows cell growth [1]. Perfect p53 protein levels are raised and cell engraftment is induced by fenbendazole (1 uM; 24 hours) [1]. Human NSCLC cells undergo the mitotic phase of the cell life cycle when exposed to 1 uM of fenbendazole for 24 hours [1]. Azole (1 uM; 24 hours) can partially alter the A549 cells' microtubule network [1].
|
|---|---|
| ln Vivo |
For 12 days, fenbendazole (1 mg; oral; once daily) can dramatically reduce the weight and size of tumors [1].
|
| Cell Assay |
Cell cycle analysis [1]
Cell Types: A549 cells Tested Concentrations: 1 uM Incubation Duration: For 24 h Experimental Results: Caused an early increase in cyclin B1/CDK1 levels (8 hrs (hours) compared to 16 hrs (hours) for control untreated cells). p-Histone H3 (Ser10) was found to be upregulated at 12 and 24 hrs (hours). Apoptosis analysis [1] Cell Types: A549 Cell Tested Concentrations: 1 uM Incubation Duration: 8, 16, 24, 32, 40, 48 hrs (hours) Experimental Results: The number of apoptotic cells increased in a time-dependent manner, along with cyclin B1 levels diminished, and approximately 30% of the cells underwent apoptosis after 32 hrs (hours). Western Blot Analysis[1] Cell Types: H460 Cell Tested Concentrations: 1 uM Incubation Duration: 24 hrs (hours) Experimental Results: Resulted in increased p53 protein levels in mitochondrial fractions. |
| Animal Protocol |
Animal/Disease Models: Female athymic nu/nu (nude) mice xenografted with A549 cells[1]: 1 mg/mouse
Route of Administration: Oral; every other day for 12 days Experimental Results: Result in significant reduction in tumor size and weight . The resulting decrease in hemoglobin content in the tumor means a decrease in the tumor's vascular supply. |
| References | |
| Additional Infomation |
Fenbendazole is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections. It has a role as an antinematodal drug. It is a member of benzimidazoles, a carbamate ester and an aryl sulfide.
Fenbendazole is a benzimidazole that presents a wide spectrum anthelmintic effect. It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and Strongyloides. Fenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. Antinematodal benzimidazole used in veterinary medicine. See also: Bacitracin methylenedisalicylate; Fenbendazole (component of); Fenbendazole; Ivermectin; Praziquantel (component of). Drug Indication For the treatment and control of gastro-intestinal nematodes in pigs infected with: Ascaris suum (adult, intestinal and migrating larval stages); Oesophagostomum spp. (adult stages); Trichuris suis (adult stages). For the treatment of gastro-intestinal nematodes in chickens infected with: Ascaridia galli (L5 and adult stages); Heterakis gallinarum (L5 and adult stages); Capillaria spp. (L5 and adult stages). |
| Exact Mass |
299.072
|
|---|---|
| CAS # |
43210-67-9
|
| Related CAS # |
Fenbendazole-d3;1228182-47-5
|
| PubChem CID |
3334
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
541.4±42.0 °C at 760 mmHg
|
| Melting Point |
233°C
|
| Flash Point |
281.2±27.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.679
|
| LogP |
4.34
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
363
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C2=C(C=1[H])N([H])C(N([H])C(=O)OC([H])([H])[H])=N2
|
| InChi Key |
HDDSHPAODJUKPD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H13N3O2S/c1-20-15(19)18-14-16-12-8-7-11(9-13(12)17-14)21-10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)
|
| Chemical Name |
methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate
|
| Synonyms |
Hoe881vHoe-881v Fenbendazole FenbendazolPanacurFenbendazoleamine Phenbendasol Safe-quard Hoe 881v
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~33.41 mM)
H2O : ~1 mg/mL (~3.34 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04920292 | COMPLETED | Drug: Oxfendazole Drug: Placebo |
Filariasis | Swiss Tropical & Public Health Institute | 2022-04-21 | Phase 1 |
| NCT06367361 | NOT YET RECRUITING | Drug: Oxfendazole Drug: Triclabendazole |
Fascioliasis | Universidad Peruana Cayetano Heredia | 2025-01-30 | Phase 2 |
| NCT02234570 | COMPLETEDWITH RESULTS | Drug: Oxfendazole Other: Placebo |
Neurocysticercosis | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-11-17 | Phase 1 |
| NCT00516945 | COMPLETED | Drug: Lamivudine | Hepatitis B Neoplasms |
Hospital Authority, Hong Kong | 2004-09 | Not Applicable |
| NCT03035760 | COMPLETEDWITH RESULTS | Drug: Oxfendazole | Helminthic Infection | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-05-12 | Phase 1 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
